Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...

Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress         8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress ...

Genomics In Cancer Care Global Market to Grow by 19.72% Annually Through 2029 Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Genomics In Cancer Care Market Analysis by Product, by Application, by Technology, End user and by Region - Global Forecast to 2029" report has been...

Global Genetic Testing Market Report 2020-2024: What Key Interest is Driving Direct to Consumer? Dublin, Oct. 13, 2020 (GLOBE NEWSWIRE) -- The "The Global Genetic Testing Market by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic and Direct to Consumer, With Executive and Consultant Guides...

Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain Waltham, MA, May 15, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. received great interest from their presentations at the International Society for Extracellular Vesicles (ISEV) 2018 in...